Detection of Autoantibodies

Autoantibodies and Autoimmunity: Molecular Mechanisms in Health and Disease

Volumn , Issue , 2006, Pages 157-188

  Burlingame, Rufus W ^a   Peebles, Carol ^a  

^a INOVA DIAGNOSTICS INC   (United States)

Author keywords

Autoantibodies; Autoantibodies as diagnostic markers; Autoimmunity; Common techniques; Common tests; Comparison of multiplexed assays; Detection of autoantibodies

Indexed keywords

EID: 84889821028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527607854.ch8     Document Type: Chapter

References (77)

1. Von Mühlen CA, EM Tan. Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases. Semin Arthritis Rheum. 1995. 24:323-358.
2. Anderson JR, Gray KG, Beck JS, Buchanan WW, McElhinney AJ. Precipitating auto-antibodies in the connective tissue diseases. Ann. Rheum. Dis. 1962. 21:360-369.
3. Carpenter AB. Antibody based methods. In: Manual of Clinical Laboratory Immunology, 6th ed. Rose NR, Hamilton RG, Detrick B, eds. ASM Press, Washington, DC. 1997.
4. Dieterich W, Ehnis T, Bauer M, Volta U, Riecken EO, Schuppan D. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997. 3:797-801.
5. Shellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998, 101:273-281.
6. Czaja AJ, Cassani F, Cataleta M, Valenti-ni P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996. 24:1068-1073.
7. Luettig B, Boeker KH, Schoessler W, Will H, Loges S, Schmidt E, Worman HJ,Gershwin ME, Manns MP. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. JHepatol. 1998. 28:824-828.
8. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am JGastroenterol. 2002. 97:413-419.
9. Teml A, Kratzer V, Schneider B, Lochs H, Norman GL, Gangl A, Vogelsang H, Reinisch W. Anti-Saccharomyces cerevi-siae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003. 98:2226-2231.
10. Van Venrooj WJ and Maini RN editors: Manual of Biological Markers of Disease, section B: Autoantigens 1994. Kluwer Academic Publishing, Boston.
11. Rose NR, Hamilton RG, Detrick B editors: Manual of Clinical Laboratory Immunology, sixth edition, 2002. ASM Press, Washington, D.C.
12. Wild D editor: The Immunoassay Handbook, second edition 2001. Nature Publishing Group, New York.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1983. 25:1271-1277.
14. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ,Takasaki Y, Wiik A, Wilson MR, Koziol JA. Range of Antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997. 40:1601-1611.
15. Harmon C, Deng JS, Peebles CL, Tan EM. The importance of tissue substrate in the SS-A/Ro antigen-antibody system. Arthritis Rheum 1984. 27:166-173.
16. Miyachi K, Fritzler MJ, Tan EM. Autoan-tibody to a nuclear antigen in proliferating cells. J Immunol. 1978. 121:2228-2234.
17. Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci. 1980. 77:1628-1631.
18. Koh WH, Dunphy J, Whyte J, Dixey J, McHugh NJ. Characterisation of anti-cytoplasmic antibodies and their clinical associations. Ann Rheum Dis. 1995. 54:269-273.
19. Monce NM Jr, Cappel VL, Saqueton CB. A comparison of two fixatives on IFA HEp-2 slides for the detection of antinuclear antibodies. J Immunoassay. 1994. 15:55-68.
20. Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, Lahita R, Maini RN, Reeves W, Reichlin M, Roth-field N, Takasaki Y, van Venrooij WJ, Tan EM. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluor-escence and western blotting. Arthritis Rheum. 1997. 40:413-418.
21. Tonuttia E, Bassetti D, Piazza A, Visen-tini D, Poletto M, Bassetto F, Caciagli P, Villalta D, Tozzoli R, Bizzaro N. Diagnostic accuracy of ELISA methods as an alternative screening test to indirect im-munofluorescence for the detection of antinuclear antibodies. Evaluation of five commercial kits. Autoimmunity. 2004. 37:171-176.
22. Russell AS, Johnston C. Relative value of commercial kits for ANA testing. Clin Exp Rheumatol. 2003. 21:477-480.
23. Wold RT, Young FE, Tan EM, Farr RS. Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid. Science. 1968. 161:806-807.
24. Rubin RL, Joslin FG, Tan EM. An improved ELISA for anti-native DNA by elimination of interference by anti-his-tone antibodies. J Immunol Methods. 1983. 63:359-366.
25. Aarden LA, deGroot ER, Feltkamp TEW. Immunology of DNA. III. Crithidia luci-liae, a simple substrate for the determination of anti-dsDNA with the immuno-fluorescence technique. Ann NY Acad Sci. 1975. 254:505-515.
26. Werle E, Blazek M, Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus. 1992. 1:369-377.
27. Tipping PG, Buchanan RC, Riglar AG, Dimech WJ, Littlejohn GO, Holdsworth SR. Measurement of anti-DNA antibodies by ELISA: a comparative study with Crithidia and a Farr assay. Pathology. 1991. 23:21-24.
28. Hylkema MN, van Bruggen MC, ten Hove T, de Jong J, Swaak AJ, Berden JH, Smeenk RJ. Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J Autoimmun. 2000. 14:159-68.
29. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int. 2000. 57:846-862.
30. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, Tervaert JW. Antiproteinase 3- and anti-myeloperoxidase-associated vasculitis. Kidney Int. 2000. 57:2195-2206.
31. Schonermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford). 2001.40:178-184.
32. Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cyto-plasmic antibodies (p-ANCA) using im-munofluorescence microscopy. Clin Exp Immunol. 2001. 126:37-46.
33. Van Meensel B, Hiele M, Hoffman I, Vermeire S, Rutgeerts P, Geboes K, Bos-suyt X. Diagnostic accuracy of ten second-generation (human) tissue transglu-taminase antibody assays in celiac disease. Clin Chem. 2004. 50:2125-2135.
34. Rutz R, Ritzler E, Fierz W, Herzog D. Prevalence of asymptomatic celiac disease in adolescents of eastern Switzerland. Swiss Med Wkly. 2002 132:43-47.
35. McPherson RA. Commentary: advances in the laboratory diagnosis of celiac disease. J Clin Lab Anal. 2001. 15:105-107.
36. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand. 1940. 17:172-178.
37. Tuffanelli DL, Wuepper KD, Bradford LL, Wood RM. Fluorescent treponemal-antibody adsorption tests: studies of false-positive reactions to tests for syphilis. N Engl J Med. 1967. 276:258-262.
38. Hargraves MM, H Richmond and R Moreton. Presentation of two bone marrow elements: The "tart" cells and the "L.E." cell. Mayo Clin Proc. 1948. 27:25-28.
39. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004. 50:380-386.
40. Wener MH: Rheumatoid Factors. Manual of Clinical Laboratory Immunology, sixth edition, 2002. ASM Press, Washington, D.C. 961-972.
41. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breed-veld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000. 43:155-163.
42. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrul-linated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004. 63:1079-1084.
43. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997. 40:1725.
44. Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive sero-logical test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol. 1984. 56:193-199.
45. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Β-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990. 87:4120-4124.
46. Galli M, Comfurius P, Maassen C, Hem-ker HC, De Baets MH, Van Breda-Vries-man PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990. 335:1544-1547.
47. Urbanus RT, de Laat HB, de Groot PG, Derksen RH. Prolonged bleeding time and lupus anticoagulant: a second paradox in theantiphospholipid syndrome. Arthritis Rheum. 2004 Nov;50(11):3605-3609.
48. Holman R and HR Deicher. The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucleoprotein of the cell nucleus. J Clin Invest 1959. 38:2059-2072.
49. Lachman PJ: An attempt to characterize the lupus erythematosus cell antigen. Immunology. 1961. 4:153-163.
50. Schett G, Rubin RL, Steiner G, Hies-berger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum. 2000. 43:420-428.
51. Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin Lab Med 1997; 17:367-377.
52. Burlingame RW. Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies. Clin Appl Immun Rev. 2004. 4:351-366.
53. Tan EM. Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology. Advances in Immunology 1989. 44:95-151.
54. Rosa MD, Hendrick Jr JP, Lerner MR, Steitz JA, and Reichlin M. A mammalian tRNA His-containing antigen is recognized by the polymyositis-specific antibody anti-Jo-1. Nucleic Acids Re. 1983. 11:853-870.
55. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chro-matin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994. 94:184-192.
56. Burlingame RW and Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991. 88:680-690.
57. Murakami A, Kojima K, Ohya K, Imamura K, Takasaki Y. A new conforma-tional epitope generated by the binding of recombinant 70-kdprotein and U1 RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connective tissue disease. Arthritis Rheum. 2002. 46:3273-3282.
58. Boire G, Lopez-Longo FJ, Lapointe S, Menard HA. Sera from patients with autoimmune disease recognize confor-mational determinants on the 60-kd Ro/SS-A protein. Arthritis Rheum. 1991. 34:722-730.
59. Elkon K, Skelly S, Parnassa A, Moller W, Danho W, Weissbach H, Brot N. Identification and chemical synthesis of a ribo-somal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1986. 83:7419-7423.
60. Itoh Y, Reichlin M. Autoantibodies to the Ro/SSA antigen are conformation dependent. I: Anti-60 kD antibodies are mainly directed to the native protein; anti-52 kD antibodies are mainly directed to the denatured protein. Autoimmunity. 1992. 14:57-65.
61. National Committee for Clinical Laboratory Standards. How to Define and Determine Reference Intervals in the Clinical Laboratory: Approved Guideline. 1995. NCCLS Document C28-A, Vol 15, No. 4. 771 East Lancaster Avenue, Villanova, PA 19085.
62. Ghiradello A, Doria A, Zampieri S, Tarri-cone E, Tozzoli R, Villata D, Bizzaro N, Piccoli A, Gambari PF, Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients, J Autoimmun 2004. 22:235-240.
63. Hueber W, Utz PJ, Steinman L, Robinson WH. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 2002. 4:290-295.
64. Pottel H, Wiik A, Locht H, Gordon T, Roberts-Thomson P, Abraham D, Goossens K, Dobbels C, De Bosschere K, Hul-staert F, Meheus L. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoan-tibodies in connective tissue disorders. Clin Exp Rheumatol. 2004. 22:579-588.
65. Graham KL, Robinson WH, Steinman L, Utz PJ. High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity. 2004. 37:269-272.
66. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002. 8:295-301.
67. Martins TB, Burlingame R, von Muhlen CA, Jaskowski TD, Litwin CM, Hill HR. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol. 2004. 11:1054-1059.
68. Griffin C, Sutor J, Shull B. Microparticle Reagent Optimization. 1994. Serydyn, Inc. Part No. 0347835. Indianapolis, Indiana.
69. Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, Hildreth SW, Hill HR. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol. 2002. 117:589-596.
70. Comtesse N, Heckel D, Maldener E, Glass B, Meese E. Probing the human natural autoantibody repertoire using an immunoscreening approach. Clin Exp Immunol. 2000. 121:430-436.
71. Granito A, Muratori P, Cassani F, Pap-pas G, Muratori L, Agostinelli D, Veronesi L, Bortolotti R, Petrolini N, Bianchi FB, Volta U. Anti-actin IgA antibodies in severe coeliac disease. Clin Exp Immunol. 2004. 137:386-392.
72. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, Leroy EC, Fritzler MJ. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic and clinical analysis. Arthritis Rheum. 1996. 39:1151-1160.
73. Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy Clin Exp Immunol. 2001. 126:37-46.
74. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=14120, see "Decision Summary".
75. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=14419, see "Decision summary".
76. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus. 2003. 12:692-696.
77. Buyon JP, Ben-Chetrit E, Karp S, Roubey RA, Pompeo L, Reeves WH, Tan EM, Winchester R. Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SS-A/Ro-SS-B/La system in neonatal lupus. J Clin Invest. 1989. 84:627-634.